SPMED Co., Ltd. participated in the 2025 Korea Society of Non-clinical Testing (KSNT) 50th Fall Workshop, held from October 30 to 31 at the International Convention Center Jeju (ICC JEJU), to promote its comprehensive preclinical testing and drug development support services.
Throughout the event, SPMED established itself as a strategic solution partner, emphasizing its commitment to the success of its partners' drug discovery journeys through the following highlights:
Key Highlights & Achievements
Promotion of Differentiated Preclinical CRO Capabilities: SPMED shared its specialized expertise in drug metabolism (DMPK) and toxicity assessment—critical components of early-stage drug development—drawing significant interest from pharmaceutical and biotech industry leaders.
Customized Technical Consultations: At the SPMED booth, our experts provided 1:1 consultations on optimizing preclinical study designs. A key focus was the innovative integration of pharmacogenomics-based precision medicine solutions into the preclinical phase to enhance predictive accuracy.
Strengthening Strategic Partnerships: By engaging with preclinical experts from leading domestic pharmaceutical companies, bio-ventures, and research institutes, SPMED discussed collaborative frameworks to streamline the drug development process and foster future innovation.
Future Outlook
Building on the collaborative proposals discussed during the workshop, SPMED plans to further enhance the sophistication of its preclinical CRO services. With integrated research capabilities spanning from preclinical to clinical stages, SPMED remains dedicated to providing world-class technical support to ensure the successful global market entry of our partners' innovative drug candidates.
